Tysabri For Crohn’s: Risk Management Is Same, But Could Be Higher Hurdle

The approval of Biogen Idec/Elan's multiple sclerosis treatment Tysabri (natalizumab) for Crohn's disease will expand the use of the product's multi-layered risk management program